Surgical Excision Margins for Melanoma (MelMarT-II Trial)
Trial Summary
The trial does not specify if you need to stop taking your current medications. However, if you are taking oral or injected immunosuppressive agents, you may not be eligible to participate.
Wide local excision (WLE) is the standard treatment for localized primary cutaneous melanomas, and it is generally effective in reducing the risk of local recurrence when appropriate margins are achieved.
12345The research does not provide specific safety data for wide local excision (WLE) in humans, but it is a standard surgical procedure used for treating melanoma, suggesting it is generally considered safe.
34567This treatment involves surgically removing melanoma with either a 1 cm or 2 cm margin around the tumor, which is less extensive than the historically recommended 3 to 5 cm margins. Studies suggest that these narrower margins do not increase the risk of cancer returning or affect survival rates, making it a more conservative and potentially less invasive option.
248910Eligibility Criteria
Adults over 18 with stage II primary invasive cutaneous melanoma, as defined by specific criteria, who can undergo surgery within 120 days of diagnosis. They should have a life expectancy of at least five years and be able to consent and follow the trial protocol. Those with certain types of melanoma or past cancers (except some successfully treated ones) are excluded.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Primary invasive cutaneous melanoma
- Primary invasive cutaneous melanoma